REVIA · Retatrutide

REVIA contains Retatrutide, a 39-amino acid synthetic peptide engineered to interact with three distinct metabolic receptor pathways simultaneously. Classed as a triple agonist targeting GLP-1, GIP, and glucagon receptors, Retatrutide represents one of the most structurally complex metabolic research compounds currently available. Research examines three primary mechanisms. Triple receptor pathway analysis: Phase 2 clinical trials published in the New England Journal of Medicine (2023) examined Retatrutide's simultaneous engagement of GLP-1, GIP, and GCGR pathways, allowing researchers to study metabolic homeostasis at a multi-tiered level not possible with single or dual agonist compounds. Metabolic efficiency modelling: By engaging GLP-1 and GIP pathways concurrently, research examines synergistic effects on insulin signalling and satiety mechanisms in cellular and tissue models. Lipid metabolism and energy expenditure: GCGR engagement is studied for its influence on hepatic lipid metabolism and energy expenditure pathways, with research examining direct effects in liver tissue models. Extended half-life: Retatrutide is synthetically modified to resist rapid enzymatic degradation, enabling stable cellular interaction over extended durations in laboratory settings. For laboratory research use only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.